Similar to pancreatic cancer, targeting other genomic alterations such as DNA damage repair genes, HER2 amplification or activation, and NTRK gene fusions can improve survival compared to conventional systemic chemotherapy alone (74). This evidence concerns the gene ERBB2 and familial pancreatic carcinoma.